Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (13) clinical trials

The primary objective of this study is to determine whether treatment with an oral investigational drug can slow cognitive decline compared with placebo treatment in individuals who are asymptomatic but at high risk for Alzheimer's disease. Asymptomatic means that the individual is not currently experiencing any symptoms of memory loss ...


A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

This study will assess the effects of each of the two therapies given separately, both targeting amyloid, on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of Alzheimer's disease (AD). Cognitively unimpaired individuals with two APOE4 genes and age 60 to ...


An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

This is a randomized (study drug assigned by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), multi-center (more than one hospital or medical school team work on a medical research study), placebo-controlled, parallel-group study in participants who are asymptomatic and at risk for ...


Tryptophan MRI in People With Schizophrenia and Healthy Controls

There is emerging evidence to suggest that disturbances in the kynurenine pathway may be related to the pathophysiology of schizophrenia. Several post-mortem studies have documented specific abnormalities in the kynurenine pathway, including increased levels of kynurenine and kynurenic acid (KYNA) in the prefrontal cortex of people with schizophrenia (1-4). Increased ...


Maraviroc and NeuroAIDS Pathogenesis

We hypothesize that maraviroc (MVC) will lead to improved cognition as assessed by improvement in neuropsychological (NP) performance. We hypothesize that MVC therapy leads to (1) decrease in HIV infection of monocytes (MO), particularly of CD16-expressing MO and (2) phenotypic and functional secretory changes suggestive of decrease in MO immune ...


Evaluation of the Efficacy Safety and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities. The study participants will be randomized to either sarizotan between 2 and 10 mg bid or placebo bid, based on age and ...


Dementia Early Recognition and Response in Primary Care

Dementia presents many challenges for primary care. Early diagnosis is important as this allows those with dementia and their family care networks to engage with support services and plan for the future. These actions can relieve the significant psychological distress that people with dementia and close supporters may experience , ...


Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)

After randomization, there is a placebo-controlled parallel group treatment with 10 mg OLN in combination with the standard treatment of Riluzole (100mg/day)(Group 1) in comparison to treatment with placebo in combination with 100 mg RIL (Group 2). Study drug will be provided as 5 mg tablets. OLN will be begun ...


Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen

This is a two-part, multi-center, prospective, randomized, placebo-controlled, parallel-group study, in which adolescent subjects with schizophrenia will be enrolled. Overall, eligible subjects will be randomized in a pre-defined 1:1 ratio to NaBen® or placebo. This study will be conducted in two parts: In Part 1 (Phase IIb) of the study, ...


Transcranial Magnetic Stimulation (TMS) in Schizophrenia

Research of deep TMS treatment in patients with schizophrenia experiencing auditory hallucinations, double blind placebo(sham) controlled study October 14, 2007 Physical background Modern TMS began in 1985 when Barker and colleagues in Sheffield, UK, developed the first TMS device. However, the original commercially available stimulators were limited in the frequency ...